DexCom recently announced a $750 million share buyback program and reaffirmed its revenue growth guidance of 14% for 2025, coinciding with its earnings report for the first quarter showing increased ...

DexCom recently received a warning letter from the FDA, which pointed out issues in manufacturing processes and quality management. While these regulatory developments did not impact its ability to ...

DexCom beat expectations in the third quarter, and it raised its revenue guidance for the full year. Manufacturing issues are putting pressure on margins. For 2026, the company sees growth missing ...

DexCom, Inc. reduced its 2024 revenue guidance following a decline in new U.S. customers and revenue per customer, leading to a sharp share price drop, despite $750 million share buyback. DexCom faces ...